Health Economics and Modeling
Rigorous economic modeling and analyses that deliver compelling evidence payers need, de-risking development and strengthening reimbursement cases.
Build the Evidence Payers Need to Say Yes
Demonstrating economic value is critical to securing reimbursement and achieving optimal pricing.
Our Health Economics and Modeling capabilities deliver rigorous, decision-grade analyses that answer fundamental payer questions about cost-effectiveness, budget impact, and long-term value.
From early development through post-launch, we generate the evidence that strengthens your case and de-risks your access strategy.
Economic Analysis and Modeling
Cost-Effectiveness Modeling
Develop robust economic models that demonstrate value relative to existing treatments.
We build cost-utility analyses, cost-effectiveness analyses, and cost-benefit models tailored to HTA body requirements and payer decision frameworks across multiple markets.
Budget Impact Analysis
Quantify the financial implications of adopting your therapy within healthcare systems.
Our budget impact models address payer affordability concerns, forecast uptake scenarios, and support pricing negotiations with transparent, defensible assumptions.
Revenue Forecasting and Pricing Modeling
Project commercial outcomes across pricing scenarios, market dynamics, and competitive landscapes.
Our forecasting models integrate epidemiological data, treatment pathways, market access timelines, and pricing assumptions to inform strategic decision-making and investor communications.
Strategic Advisory and Evidence Planning
Early Health Economic Strategy and Advisory
Align clinical development with payer evidence requirements from the start.
We provide strategic counsel on endpoint selection, comparator choice, study design, and data collection to ensure your trials generate the economic evidence needed for reimbursement success.
Value Assessment and Gap Analysis
Identify evidence gaps and access risks at critical development milestones.
Our assessments evaluate clinical, economic, and budget impact evidence against HTA and payer requirements, providing actionable recommendations to optimize evidence generation and strengthen submissions.
Early Engagement and Scientific Advice Support
Facilitate dialogue with HTA bodies, payers, and regulatory agencies to clarify evidence expectations and reduce uncertainty.
We coordinate parallel scientific advice, joint consultations with EMA and HTA bodies, and early payer engagement to align development plans with decision-maker priorities.
Why It Matters
HTA bodies and payers increasingly demand robust economic evidence to justify reimbursement decisions.
Without Strong Health Economics:
- Reimbursement is delayed or denied – Weak economic cases lead to unfavorable coverage decisions
- Pricing is pressured – Inability to demonstrate value results in lower prices or restrictive access
- Market potential is lost – Poor evidence planning can cost up to 60% of a product’s potential value
- Competitive position weakens – Competitors with superior evidence capture market share
Strong Health Economics Delivers:
- Faster reimbursement approvals – Evidence that meets decision-maker expectations accelerates access by 4-6 months on average
- Optimal pricing outcomes – Compelling economic cases support price justifications and reduce pricing discounting pressure
- Smarter investment decisions – Early economic assessments inform go/no-go decisions and development priorities
- Competitive differentiation – Superior economic evidence positions your innovation ahead of alternatives
Our Approach
We combine technical excellence with strategic insight to deliver health economics that works in the real world. Our teams bring:
- Deep expertise in HTA methodologies, payer decision frameworks, and economic modeling best practices, with over 300 models developed or adapted across therapeutic areas in the past 5 years
- Understanding of country-specific requirements across geographies
- Integration with regulatory affairs, and clinical development to ensure evidence alignment
- Experience with innovative therapies including cell and gene therapies, digital therapeutics, rare diseases, and precision medicines
- Proven track record supporting successful reimbursement outcomes across therapeutic areas, with the vast majority +9of our economic models accepted by HTA bodies on first submission
- Advanced digital capabilities leveraging AI and data analytics to enhance model accuracy and efficiency
Whether informing early development decisions, supporting HTA submissions, or defending value post-launch, our health economics capabilities ensure your evidence is rigorous, relevant, and persuasive.
Ready to build a compelling economic case for your innovation?
Contact us to discuss your health economics needs.
PLG's team has been essential in defining our entry strategy in Europe due to their deep expertise and first-class service quality.
European Market Access Director